A Research Trial of Aralast in New Onset Diabetes (RETAIN)

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

Aralast NP 45 mg dose

\- 45 mg/kg/week

BIOLOGICAL

Aralast NP 90 mg dose

\- 90 mg/kg/week

BIOLOGICAL

Aralast NP 180 mg dose

\- 180 mg/kg/week

Trial Locations (15)

10032

Naomi Berrie Diabetes Center (Columbia University), New York

19104

Children's Hospital of Philadelphia, Philadelphia

21201

University of Maryland Medical Center, Baltimore

30309

Atlanta Diabetes Associates, Atlanta

30322

Children's Hospital of Atlanta (Emory University), Atlanta

43205

Nationwide Children's Hospital, Columbus

52242

University of Iowa Children's Hospital, Iowa City

64108

Children's Mercy Hospital, Kansas City

80045

Barbara Davis Center (University of Colorado), Aurora

92093

RADY Children's Hospital (University of California, San Diego), San Diego

98122

Pacific Northwest Research Institute-University of Washington, Seattle

06520

Yale University, New Haven

02114

Massachusetts General Hospital, Boston

02215

Joslin Diabetes Center, Boston

01655

University of Massachusetts Memorial Medical Center, Worcester

Sponsors
All Listed Sponsors
collaborator

Immune Tolerance Network (ITN)

NETWORK

collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH